foscarnet has been researched along with Thyroid Carcinoma, Anaplastic in 2 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
Thyroid Carcinoma, Anaplastic: An aggressive THYROID GLAND malignancy which generally occurs in IODINE-deficient areas in people with previous thyroid pathology such as GOITER. It is associated with CELL DEDIFFERENTIATION of THYROID CARCINOMA (e.g., FOLLICULAR THYROID CARCINOMA; PAPILLARY THYROID CANCER). Typical initial presentation is a rapidly growing neck mass which upon metastasis is associated with DYSPHAGIA; NECK PAIN; bone pain; DYSPNEA; and NEUROLOGIC DEFICITS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Foscarnet was administered given the positivity for FGF2, FGFR1 and FGFR4 in ATC." | 1.46 | Anaplastic thyroid carcinoma and foscarnet use in a multitarget treatment documented by 18F-FDG PET/CT: A case report. ( Baroli, A; Bulzonetti, N; Carletti, R; Di Gioia, C; Durante, C; Filetti, S; Gianfrilli, D; Giannetta, E; Graziadio, C; Isidori, AM; Lenzi, A; Longo, F; Pofi, R; Tombolini, V; Verrienti, A, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giannetta, E | 1 |
| Isidori, AM | 1 |
| Durante, C | 1 |
| Di Gioia, C | 1 |
| Longo, F | 1 |
| Tombolini, V | 1 |
| Bulzonetti, N | 1 |
| Graziadio, C | 1 |
| Pofi, R | 1 |
| Gianfrilli, D | 1 |
| Verrienti, A | 1 |
| Carletti, R | 1 |
| Filetti, S | 1 |
| Lenzi, A | 1 |
| Baroli, A | 1 |
| Rose, K | 1 |
2 other studies available for foscarnet and Thyroid Carcinoma, Anaplastic
| Article | Year |
|---|---|
Anaplastic thyroid carcinoma and foscarnet use in a multitarget treatment documented by 18F-FDG PET/CT: A case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Female; Fluorodeoxyglucose F | 2017 |
Foscarnet reduces FGF2-induced proliferation of human umbilical vein endothelial cells and has antineoplastic activity against human anaplastic thyroid carcinoma cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antiviral Agents; Binding, Competitive; Cell Line, Tu | 2013 |